The ipamorelin dosage used in medical settings and clinical trials is 0.03 mg per kg of body weight administered intravenously twice daily
The most impressive transformations come from people who treat GHK-Cu as long-term maintenance rather than a quick fix
Patients should avoid IGF-1 LR3 without medical clearance if they have blood sugar problems, diabetes risk, cancer history, abnormal growth concerns, cardiovascular disease, kidney or liver issues, active illness, pregnancy, breastfeeding, or current prescription medication use
(2) On the other hand, Ipamorelin is a synthetic peptide that appears to interact with the GHS-Rs, which are also receptors for the native hormone ghrelin, with the latter also referred to as the hunger hormone